Bloodthirsty Monster Trump’s Fake CV19 ‘Cure’ Has 45% Death Rate-Major Study (Surprised?)

Trump's COVID Auschwitz

By
VT Editors
-
1
1717

Culling the herd: VT estimates that, during the 2 months hydroxychlorquine was used based on Trump-Hannity recommendations, 10,000 Americans died from poisoning and nearly $2 Bn. went into the pockets of gangsters controlling supplies of the COVID-toxic drug which can be used just not for COVID patients…which we have asserted all along, it kills with extreme efficiency as the Lancet study below confirms

Daily Beast: A massive worldwide study of coronavirus patients has found that the malaria drug that President Trump has relentlessly promoted during the pandemic poses a significant risk of death, the Washington Post reports.

Mocking an MS patient, good natured White House humor
Trump has placed so much faith in the supposed benefits of hydroxychloroquine that he has said he is taking it himself; he also said he had taken a dose of the antibiotic azithromycin although that was not mentioned in a White House physician’s note this week.

Is David Icke right about lizard people?

The study published Friday in the medical journal the Lancet, shows that this cocktail of drugs—hydroxychloroquine plus a macrolide antibiotic such as azithromycin—is linked to a 45 percent increased risk of death and a more than quadrupled risk of a serious heart arrhythmia.

Let’s hear from the first lady…(left)

The study looked at 96,000 hospitalized virus patients around the world and found that, overall, those given hydroxychloroquine had a 34 percent increase in risk of mortality and a 137 percent increased risk of a serious heart arrhythmia.

Why are we using this graphic here?

“It’s one thing not to have benefit, but this shows distinct harm,” said Eric Topol, director of the Scripps Research Translational Institute. “If there was ever was hope for this drug, this is the death of it.”

Read it at The Washington Post

The Lancet Journal

 

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Summary

Background

Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.

Methods

We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded. The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).

Findings

96 032 patients (mean age 53·8 years, 46·3% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria. Of these, 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group. 10 698 (11·1%) patients died in hospital. After controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity), when compared with mortality in the control group (9·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·223–1·457), hydroxychloroquine with a macrolide (23·8%; 1·447, 1·368–1·531), chloroquine (16·4%; 1·365, 1·218–1·531), and chloroquine with a macrolide (22·2%; 1·368, 1·273–1·469) were each independently associated with an increased risk of in-hospital mortality. Compared with the control group (0·3%), hydroxychloroquine (6·1%; 2·369, 1·935–2·900), hydroxychloroquine with a macrolide (8·1%; 5·106, 4·106–5·983), chloroquine (4·3%; 3·561, 2·760–4·596), and chloroquine with a macrolide (6·5%; 4·011, 3·344–4·812) were independently associated with an increased risk of de-novo ventricular arrhythmia during hospitalisation.

Interpretation

We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.

Funding

William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women’s Hospital.  Read more:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext

 

ATTENTION READERS
Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy

RELATED ARTICLESMORE FROM AUTHOR

1 COMMENT

  1. One thing we can say with a high degree of certainty. The actions of the federal government of the US have consistently acted to exacerbate the harmful effects of the virus and thwarted mitigation attempts over and over and over.

Comments are closed.